Brief: Hansa Biopharma Idefirix Receives Provisional Approval In Australia
11/07/2023 11:19
July 11 (Reuters) - Hansa Biopharma AB HNSA.ST :
* IDEFIRIX (IMLIFIDASE) RECEIVES PROVISIONAL APPROVAL IN
AUSTRALIA
AS DESENSITIZATION TREATMENT IN HIGHLY SENSITIZED PATIENTS PRIOR
TO KIDNEY TRANSPLANTATION
* PROVISIONAL APPROVAL HAS A DURATION OF TWO YEARS AND WAS
BASED
ON DATA FROM HANSA'S PHASE 2 STUDIES
Source text for Eikon: ID:nWkr55MGFL
Further company coverage: HNSA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS